Zymeworks’ ZW25 and ZW33 Granted Orphan Drug Designation for Ovarian Cancer by FDA

Ontario Industry Updates
Written By Guest User

Aug 18, 2016 - Vancouver - Zymeworks Inc., a biopharmaceutical company discovering and developing innovative multi-functional protein-based therapeutics, including bi-specific antibodies and drug conjugates for the treatment of cancer, announced today that the United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to Zymeworks’ lead investigational products ZW25 and ZW33 for the treatment of ovarian cancer. Orphan drug designation qualifies Zymeworks for a number of development incentives including tax credits for clinical testing and marketing exclusivity for a period of seven years if ZW25 or ZW33 is approved for this indication.

For the full press release, click here

Guest User
Previous

CAAP Company: ScarX announces approval for trial of first clinically-promising scar reduction cream
Next

Trillium Therapeutics Receives FDA Clearance to Proceed With TTI-621 in Clinical Trial Targeting Solid Tumors and Mycosis Fungoides